Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells

Wen-Hua Zheng1,2 and Rémi Quirion*2

Address: 1Department of Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China and 2Douglas Hospital Research Center, Department of Psychiatry, McGill University, Montreal, Quebec, H4H 1R3, Canada

Email: Wen-Hua Zheng - whzheng123@gmail.com; Rémi Quirion* - quirem@douglas.mcgill.ca

* Corresponding author

Abstract

Background: Insulin-like growth factor-1 (IGF-1) is a polypeptide growth factor with a variety of functions in both neuronal and non-neuronal cells. IGF-1 plays anti-apoptotic and other functions by activating multiple signaling pathways including Akt kinase, a serine/threonine kinase essential for cell survival. The nuclear transcription factor cAMP response element-binding protein (CREB) may also be involved although relationships between these two proteins in IGF-1 receptor signaling and protection is not clear, especially in neuronal cells.

Results: IGF-1, in a concentration- and time-dependent manner, induces the activation/phosphorylation of Akt and CREB in PC12 cells by activating different signaling pathways. IGF-1 induced a sustained phosphorylation of Akt while only a transient one was seen for CREB. The phosphorylation of Akt is mediated by the PI3 kinase pathway while that of CREB is dependent on the activation of both MAPK kinase and p38 MAPK. Moreover, the stimulation of PKC attenuated the phosphorylation of Akt induced by IGF-1 while enhancing that of CREB. Survival assays with various kinase inhibitors suggested that the activation/phosphorylation of both Akt and CREB contributes to IGF-1 mediated cell survival in PC12 cells.

Conclusion: These data suggest that IGF-1 induced the activation of Akt and CREB using distinct pathways in PC12 cells.

Background

Insulin-like growth factor-1 (IGF-1) is a polypeptide trophic factor playing important roles in the survival and differentiation of both neuronal and non-neuronal cells [1,2]. The biological actions of IGF-1 are mediated by a heterotetrameric tyrosine kinase receptor, the IGF-1 receptor, which is similar to the insulin receptor both in structure and functions [2,3]. Binding of IGF-1 to its receptor causes receptor autophosphorylation and the activation of intrinsic tyrosine kinase. Activated receptor kinase phosphorylates various intracellular proteins like the insulin receptor substrate-1 (IRS-1) and Shc [3-5], leading to the activation of multiple signaling pathways including the phosphatidylinositol 3 kinase (PI3K)/Akt pathways and the mitogen-activated protein (MAP) kinase (also

Published: 22 June 2006

BMC Neuroscience 2006, 7:51 doi:10.1186/1471-2202-7-51

This article is available from: http://www.biomedcentral.com/1471-2202/7/51

© 2006 Zheng and Quirion; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Akt, a key target of the PI3 kinase, is a serine/threonine kinase that plays critical roles in the modulation of cell development, growth and survival [8-10]. Stimulation of cells with IGF-1 induces the activation of PI3 kinase leading to increased levels of phosphatidylinositol [3,4] diphosphate [PI[3,4] P2] and phosphatidylinositol [3-5] triphosphate [PI [3-5] P3] in target cells [11,12]. This event recruits Akt to the plasma membrane where it is phosphorylated by PI [3-5] P3 dependent kinase, (PDK)-1 and -2, respectively at residues Thr308 and Ser473 [13,14]. The phosphorylation of these residues activates Akt kinase which can then phosphorylate its many substrates including glycogen synthase kinase-3 (GSK-3) [15], the Bcl-2 family member Bad [16], caspase-9 [17], nuclear factor-kB (NFkB) [18,19] and the winged-helix family of transcription factors, FOXO1, FOXO3a and FOXO4 [1,10,20-22], leading to cell survival and the inhibition of apoptosis [1,8,10,23].

The Ca\(^{2+}\)/cyclic AMP response element-binding protein (CREB) is one of the common nuclear targets of tyrosine kinase receptors playing important roles in many biological functions including neuronal plasticity, full axonal development, memory consolidation, and neuroprotection [24-30]. This transcriptional factor belongs to the CREB/ATF family and binds to the specific sequence, 5'-TGACGTCA-3' known as CRE [31]. Activation of this transcription factor requires the phosphorylation of the Ser-133 residue which increases its association with CREB-binding protein [32]. Several kinases including cyclic AMP-dependent protein kinase (PKA), protein kinase-C (PKC), calcium/calmodulin-dependent protein kinases, MAPK/p38 MAPK/MAPKAP kinase-2, ribosomal S6 kinase (RSK) family of kinases, the mitogen and stress-activated protein kinases 1 (MSK1) and Akt have been shown to be capable of phosphorylating this protein on Ser-133 residue [28,33-38].

IGF-1 stimulates the phosphorylation of CREB and regulates the expression of a number of CRE-containing genes including bcl-2 and c-fos in several cell types [32,39]. Interestingly, CREB is reported as a possible target of Akt [30,37] suggesting that it may be a target of Akt in IGF-1 mediated survival. However, reports about Akt as a CREB kinase in IGF-1 signalling is still rather controversial with one report suggesting that the phosphorylation of CREB induced by IGF-1 is independent on Akt [40]. Moreover, the signalling of CREB and Akt is cell type-dependent and effectors specific [41]. Therefore, it is deemed important to clarify the role of Akt in the phosphorylation of CREB induced by IGF-1. Accordingly, we characterized here the signalling of IGF-1 stimulated activation of CREB compared to that of the PI3K/Akt in PC12 cells. Our data show that IGF-1 promotes the phosphorylation of Akt and CREB in these cells. The activation of Akt is mainly mediated by the PI3 kinase pathway, while that of CREB is primarily dependent on the activation of MAPK and p38 MAP kinases revealing the differential regulation of these two proteins by IGF-1 receptor signalling. It also argues against a key role for Akt as a CREB kinase in PC12 cells. The survival study suggests that the activation of these two proteins likely contributes to the survival effects of IGF-1 in PC12 cells, with the PI3K/Akt kinase pathway playing a predominant role.

**Results**

**IGF-1 stimulates the phosphorylation of Akt and CREB in PC12 cells**

To investigate the effect of IGF-1 on the activation/phosphorylation of Akt and CREB in neuronal cells, PC12 cells were treated with 1–100 nM IGF-1 and the phosphorylation of Akt and CREB evaluated as described in Methods. Figure 1 shows that IGF-1 induced the sustained phosphorylation of Akt while a transient phosphorylation was seen for CREB. In the case of CREB, one additional band with a lower molecular weight was seen in the blot. This band represents p-ATF which has 100% homologous consensus phosphorylation sequence with CREB and cross react with...
the anti-pCREB antibody [30]. Treatment of PC12 cells with 10 nM IGF-1 caused a 3–5 fold increase in the phosphorylation of Akt at Ser-473. The phosphorylation reached the highest level at 2.5 min and remained unchanged for over 40 min. The phosphorylation of CREB at Ser-133 was increased 2–3 fold by 10 nM IGF-1. The induction of CREB phosphorylation was evident at 5 min, peaked at about 10 min and decreased thereafter (Fig 1A). IGF-1 also concentration-dependently stimulated the phosphorylation of Akt and CREB in PC12 cells. The effect of IGF-1 on Akt was seen at concentration as low as 0.33 nM while about 3 nM was required to induce the phosphorylation of CREB (Fig 1B).

To extend these results further, wortmannin, another well known PI3 kinase inhibitor, was investigated in our model. Wortmannin (100 nM) had no effect on IGF-1 stimulated phosphorylation of CREB but most significantly blocked that of Akt demonstrating further the differential mechanisms used by IGF-1 to regulate their phosphorylation (Figure 3B).

MAPK kinase and p38 MAP kinase inhibitors concentration-dependently inhibit IGF-1-induced phosphorylation of CREB
To investigate in detail the role of MAPK and p38 MAPK kinases on the phosphorylation of CREB, well established inhibitors of these two pathways were used. As shown in Figure 4, the MAPK pathway inhibitor, PD98059, concentration-dependently inhibited IGF-1 stimulated phosphorylation of CREB (Fig 4A) and MAP kinase (Fig 4B). Similarly, Figure 5 shows that the phosphorylation of p38 MAPK and CREB is concentration-dependently inhibited by a p38 MAPK specific inhibitor, PD169316.

PMA attenuates IGF-1-induced phosphorylation of Akt while increasing CREB phosphorylation
We have previously shown that the activation of PKC by PMA attenuated the phosphorylation of Akt induced by IGF-1 [42]. We explored here the effects of such a treatment on Akt versus CREB phosphorylation induced by IGF-1. Pretreatment with PMA attenuated the tyrosine phosphorylation of IRS-1 as we reported in our previous study [42], and Akt while enhancing the phosphorylation of CREB (Fig 6).

Treatment with a tyrosine kinase inhibitor blocks IGF-1 receptor signaling, including the phosphorylation of Akt and CREB
Having established that IGF-1 stimulated the phosphorylation of Akt via a PI3 kinase pathway while MAPK and p38 MAPK pathways mediated the activation of CREB, we studied next the upstream events involved in these effects. IGF-1 stimulated the tyrosine phosphorylation of IRS-1R (Fig 7A, lane 3 vs lane 1). IRS-1 (Fig 7B,
lane 3 vs lane 1) and its association with PI3 kinase (Fig 7A and 7B, lane 3 vs lane 1), as well as those of Akt and CREB (Fig 7C lane 3 vs lane 1). Pretreatment with the tyrosine kinase inhibitor, herbimycin A, inhibited these actions of IGF-1 (Fig. 7A, 7B and 7C, lane 4 vs lane 3). Hence, the tyrosine phosphorylation of the IGF-1 receptor is essential for the activation/phosphorylation of these downstream signaling proteins.

Both Akt and CREB can contribute to the survival effects of IGF-1 in PC12 cells

Figure 8 shows that various kinase inhibitors for Akt, MAPK and p38 MAPK significantly attenuated the survival effects of IGF-1 with the PI3K/Akt kinase inhibitor being the most effective. Hence, while the PI3K/Akt pathway plays a major role in the protective effects of IGF-1, the MAPK/CREB pathway is also significantly involved even if to the lesser extent (Fig. 8).

Effects of other trophic factors and agents in the phosphorylation of CREB

To compare the effect of other factors and agents to that of IGF-1 on the phosphorylation of CREB, PC12 cells were treated with IGF-1, EGF, FGF, FBS, PMA and the calcium ionophore A23187, and the phosphorylation of CREB. Treatments with 4 nM EGF, 4 nM FGF, 10% FBS, 200 nM PMA and 10 µM A23187 significantly stimulated the phosphorylation of CREB that are comparable to the effect of IGF-1 (Fig 9).

Discussion

The present study demonstrates that IGF-1 is able to time- and concentration-dependently stimulates the activation of both Akt and CREB in PC12 cells. The activation of Akt by IGF-1 is mediated by the PI3 kinase pathway while MAPK and p38 MAPK are involved in IGF-1 induced pathway.
phosphorylation of CREB. Survival assay revealed that these various pathways contribute to the survival effects of IGF-1 in PC12 cells.

IGF-1 is a polypeptide trophic factor capable of supporting growth and of preventing death in neuronal and non-neuronal cells. The biological functions of this growth factor are mediated by IGF-I receptors. Recent studies have shown that both IGF-1 and its receptors are expressed in the CNS [1,21,43], and their respective expression is upregulated in response to injuries [1,44]. It is also well established that IGF-1 protects the brain from hypoxic and ischemic injuries [45]. IGF-1 is also neuroprotective in a broad range of cells including cultured primary hippocampal neurons. These neuroprotective effects likely involve multiple signaling pathways but in particular the PI3K/Akt kinase and MAPK-CREB pathways [2,30,46,47]. Consistent with these findings, our results show here that IGF-1 is able to stimulate the activation of both the PI3K/Akt kinase and MAPK-CREB pathways in PC12 cells.

Although mechanisms underlying the phosphorylation of CREB have been extensively studied, the role of a given signaling pathway in mediating the effect of a trophic factor on CREB remains somewhat controversial. For example, while Akt has been suggested to act as a 'CREB kinase', data obtained here are not fully supportive of such an hypothesis. Indeed, while IGF-1 induced the sustained phosphorylation of Akt, only a transient one was seen for CREB. Moreover, inhibitors of PI3K/Akt blocked the activation/phosphorylation of Akt with almost no effect on the phosphorylation of CREB. In contrast, MAPK and p38 kinase inhibitors significantly diminished IGF-1-induced phosphorylation of CREB while only having a small effect on Akt. Indeed, the MAPK pathway inhibitor PD98059 and the p38 MAPK kinase inhibitor, PD169316, at concentrations fully inhibiting MAPK and p38 kinase respectively, significantly abrogated the phosphorylation of CREB while having no significant effect on the activation of Akt. Moreover, the phosphorylation of CREB induced by IGF-1 is not inhibited by Akt inhibitors at concentrations that fully blocked the phosphorylation of GSK3β, a target of Akt in the IGF-1 signaling pathway (data not shown). Finally, PMA, an activator of PKC, attenuated IGF-1-induced activation of Akt while enhancing the phosphorylation of CREB. Taken together, these data reveal that IGF-1-induced phosphorylation of Akt and CREB is mediated via distinct pathways and suggest that
CREB is not a direct substrate of Akt in IGF-1 receptor signaling in PC12 cells. In fact, MAPK and p38 MAPK most likely contribute to the phosphorylation of CREB stimulated by IGF-1 in PC12 cells. However, the existence of kinase(s) which can actually phosphorylate CREB at Ser-133 has not been reported in PC12 cells. MAPK and p38 MAPK cannot directly phosphorylate CREB at this residue as it is not a proline-directed phosphorylation site [41]. Downstream targets of these two kinases that may be able to phosphorylate CREB in PC12 cells include the ribosomal S6 kinase (RSK) family of kinases, MAPKAP kinase 2/3 and MSK1/2. For example, the over-expression of inhibitory RSK2 mutants reduced EGF-induced CREB phosphorylation [36] while cells deficient for this kinase were found to be resistant to EGF-stimulated CREB phosphorylation [48]. However, Rsk-2-deficient cell lines have shown that this kinase is not essential for the activation of CREB in response to PDGF and IGF-1 [49].

MAPKAP kinase-2, an enzyme immediately downstream of p38 MAP kinase, is able to phosphorylate CREB at Ser133 in vitro, and has been suggested to play an important role in FGFR- or stress-induced phosphorylation of CREB and ATF-1 in SK-N-MC cells [34]. However, a subsequent report using PC12, HeLa and SK-N-MC cell lines...
failed to demonstrate a role for both RSK2 and MAPKAP-2/3 as CREB kinases in signalling induced by TNF, NGF and FGF [50]. The potential role of this kinase in IGF-1 induced CREB phosphorylation in PC12 cells hence remains to be fully established.

MSK1 is a downstream kinase of the MAPK and p38 MAPK kinase pathways and is important in stress and mitogen-induced CREB phosphorylation in fibroblasts, PC12 cells and embryonic stem cells [38,50-52]. Since both MAPK and p38 MAPK are involved in IGF-1 induced phosphorylation of CREB in PC12 cells, MSK1 is thus a possible intermediate step. Consistent with this hypothesis, preliminary data have shown that blockade of MSK1 significantly inhibited IGF-1 stimulated phosphorylation of CREB in PC12 cells (Zheng and Quirion, unpublished results).

The biological significance of the finding that distinct pathways are involved in IGF-1 induced phosphorylation of Akt and CREB is not clear. Both proteins are known to play central roles in cell survival [9,46,47,53]. The role of Akt in cell survival was proposed first by Dudek and colleagues (1997) in a study showing that IGF-1-induced survival of cultured cerebellar granule cells was mediated by this kinase [9]. Subsequently, Akt was shown to be a key survival promoting kinase for a broad of range of factors in a variety of cell type [1,22,46,47]. It is known that activated Akt can phosphorylate and hence inactivate pro-apoptotic proteins such as the Bcl-2 family member Bad [16], caspase-9 [17], GSK3 [15], FOXO transcription factors [21,22,47] and ASK1 [54]. Akt can also affect the expression of Bcl-2 family members in target cells as well as the function of NF-kappaB and CREB [46,47].

The MAPK-CREB pathway was also reported to play a major role in neuronal survival including in PC12 cells [47,53]. For example, MAPK can activate RSKs and MSK1/2 [51,53]. RSKs are then able to phosphorylate the pro-apoptotic protein Bad at Ser-112 suppressing Bad-mediated apoptosis [53]. RSKs and possibly MSK1/2 are also able to facilitate the phosphorylation of CREB at Ser-133, leading to cell survival. Accordingly, the Akt and MAPK-CREB pathways likely have additive effects in contributing to the survival effects induced by IGF-1 in PC12 cells. This is also exemplified by the action of Akt and MAPK in the phosphorylation of Bad. In the presence of growth factors, Akt is activated and phosphorylates Bad at Ser-136, inhibiting its pro-apoptotic effect [16]. In parallel, the activation of MAPK leads to the phosphorylation of Ser-112 further inhibiting Bad [53]. Hence, IGF-1 by acting via the IGF-1 receptor complex and parallel downstream effectors can inhibit various pro-apoptotic signals in a variety of cells including PC12 cells.

**Conclusion**

In conclusion, this study shows that IGF-1-induced phosphorylation of Akt kinase is mediated by the PI3 kinase pathway while that of CREB is regulated mainly by activating the MAPK and p38 MAPK pathways.

**Methods**

**Materials**

Human recombinant IGF-1 was obtained as a gift from Genentech Inc (San Francisco, CA). LY294002, PD98059, herbimycin A, rapamycin, PD169316, Akt inhibitors I and II were purchased from Calbiochem (Bad Soden, Germany) whereas wortmannin, leupeptin, aprotinin, sodium vanadate and phorbol 12-myristate 13-acetate (PMA) were from Sigma Chemical (St Louis, MO). U0126 was purchased from Promega (Madison, WI). Anti-phospho-CREB, anti-CREB, anti-phospho-p38 MAPK, anti-phospho-Akt, anti-phospho-GSK3β (Ser-9) and anti-phospho-MAPK antibodies were obtained from Cell Signaling Technology (Beverly, MA). Anti-Akt, anti-MAPK, anti-p38 MAPK and all secondary antibodies conjugated with horseradish peroxidase (HRP) were from Santa Cruz Biotechnology (Santa Cruz, CA). Cell culture reagents were purchased from Gibco Life Technologies (Grand Island, NY).
Island, NY) whereas all other reagents were from Sigma Chemical or Fisher Scientific (Nepean, ON).

**Cell culture**

PC12 cells were kindly provided by Dr. Gordon Guroff at NICHD, NIH (Betheda, MD) and cultured as described before. In brief, PC12 cells were maintained in 75 cm² flasks in high glucose Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 5% (vol/vol) fetal bovine serum (FBS), 5% horse serum, 100 μg streptomycin/ml and 100 U penicillin/ml. Cells were incubated at 37°C with 5% CO₂ humidified atmosphere. Stock culture was routinely sub-cultured at 1:5 ratio at a week interval.

**Treatments**

Before each experiment, cells were detached using 5 mM EDTA in Hank's balance buffer (HBS) and seeded in 12 or 6 well plates (coated with poly-D-lysine, 10 μg/ml) at a density of 3–6 × 10⁵ cells/well in 2% serum medium for 24 hrs. Culture medium was changed with DMEM 2 hr before the desired reagents were added. To study the effect of IGF-1 on the phosphorylation of Akt, CREB, MAPK, p38 MAPK and GSK3β, cells were treated with 10 nM IGF-1 for 10 min. Alternatively, cells were pretreated with wortmannin (0–2 μM, 30 min), LY294002 (6–50 μM, 30 min), rapamycin (50 nM, 30 min), PD98059 (6–50 μM, 40 min) or PD169316 (2.5–20 μM, 40 min) followed by a stimulation with 10 nM IGF-1. For the experiments with PKC, 400 nM PMA was added to cells 2.5 min prior to IGF-1 stimulation.

**Western blotting**

Western blot was performed as described earlier with some modifications [1,23]. Briefly, treated cells from different experimental conditions were rinsed twice with ice cold HBSS and lysed in either sample buffer [62.5 mM Tris-HCl, pH 6.8, 2% w/v sodium dodecyl sulfate (SDS), 10% glycerol, 50 mM dithiothreitol (DTT) and 0.1% w/v bromphenol blue] or RIPA buffer [50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Igepal CA-630, 0.1% SDS, 50 mM NaF, 1 mM NaVO₃, 5 mM phenyl-methyl-sulfonyl fluoride, 10 μg/ml leupeptin, 10 μg/ml aprotinin]. Samples with equal amounts of protein were then separated by 4–20% polyacrylamide gel electrophoresis (PAGE), and the resolved proteins were electrotransferred to Hybond-C Nitrocellulose. Membranes were incubated with 5% non-fat milk in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 0.2% Tween-20) for 1 hr at room temperature and incubated with appropriate primary antibody at 4°C overnight. Membranes were then washed twice with TBST and probed with corresponding second antibodies conjugated with HRP (anti/rat/mouse/rabbit/goat-HRP) at room temperature for 1 hr. Membranes were finally washed several times with TBST to remove unbound secondary antibodies and visualized using an ECL detection kit (Amersham Co, Toronto, ON). A part of the SDS gel was stained with Coomassie Blue to ensure the use of equal amounts of protein.

The respective phosphorylation of Akt, MAPK, CREB, GSK3β (Ser-9) and p38 MAPK was determined by Western blot using anti-phospho-Akt, anti-phospho-MAPK, anti-phospho-CREB, anti-phospho-GSK3β (Ser-9) and anti-phospho-p38 MAPK antibodies, respectively. Blots were stripped and reprobed with anti-Akt, anti-MAPK, CREB, GSK3β and p38 MAPK antibodies to ensure that equal amounts of various proteins were present. The effect of IGF-1 was determined by comparing the phosphorylation of above protein and their unphosphorylated counterpart or beta-actin levels in cell extracts determined as mentioned above.

**Determination of tyrosine phosphorylation of the IGF-1 receptor, IRS-1 and their interactions with PI3 kinase was established by immunoprecipitation**

PC12 cells were treated with 10 nM IGF-1 for 8 min and rinsed with cold phosphate buffer saline (PBS). After centrifugation at 1000 g for 5 min at 4°C, cell pellets were lysed on ice in pre-cold RIPA buffer for 20 min. Cell lysates were then pelleted at 13,000 g for 10 min and the concentration of protein in each sample was determined using the Bio-Red dye-binding method with bovine serum albumin (BSA) as standard. The supernatant with equal amount of protein was incubated overnight at 4°C with either anti-IGF-1R, anti-IRS-1 or anti-PI3 kinase antibodies. Formed immunocomplexes were isolated by protein A/G PLUS-agarose (Santa Cruz Biotechnology, Inc.), separated by 4–20% SDS gel and then tyrosine phosphorylation was determined by Western blot with a mixture of anti-phosphotyrosine antibodies 4G10 and PY99. Blots were striped and reprobed with PI3 kinase or IRS-1 antibodies to evaluate the interaction of IGF-1R and IRS-1 with PI3 kinase. Finally, the blots were reprobed with anti-IGF-1R, anti-IRS-1 or anti-PI3 kinase to ensure the presence of equal amount of proteins.

**Cell viability using the MTT assay**

PC12 cells (10000 to 20000 cells/well) in serum -free medium DMEM or DMEM supplemented with 1% FBS were added to 96- well plates and incubated at 37°C with 5% CO₂ for 2 h. Cells were pretreated with 25 μM LY294002, 25 μM PD98059, 10 μM PD169316 for 40 min and then 1% FBS and 10 nM IGF-1 for 24–48 hours. Following replacement of the medium with 0.5 mg/ml MTT in DMEM, cells were returned into the incubator for a 3-hr period. Cells and MTT formazan crystals were then solubilized by titration in a solution of isopropanol/HCL (0.1 N) and the survival profile of these cells were quantified by spectrophotometrically measuring the plate
at 570 nM. Assays were repeated at least three to six times, each in quadruplicate.

Statistical analysis
Data are expressed as mean ± SEM. A one-way ANOVA with Newman-Keul test was used to establish statistical significance set at p < 0.05.

Authors’ contributions
WHZ did experiments, collected data and prepared manuscript. RQ contributed in manuscript preparation.

Acknowledgements
This research was supported by the Canadian Institutes of Health Research

References
1. Zheng WH, Kar S, Quirion R: Insulin-like growth factor-1-induced phosphorylation of transcription factor FKHR1 is mediated by phosphatidylinositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth factor-1-induced survival of cultured hippocampal neurons. Mol Pharmacol 2002, 62(2):225-233.
2. Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y, LeRoith D: Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B, Biochem Mol Biol 1998, 121(1):19-26.
3. LeRoith D, Werner H, Beiter-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995, 16(2):143-163.
4. Myers MG Jr, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM, White MF: IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. Endocrinology 1993, 132(4):1421-1430.
5. Sasaoka T, Rose DW, Jhin BH, Saito AR, Draznin B, Olefsky JM: Evidence for a functional role of Shc proteins in mitogenic signal transduction induced by insulin, insulin-like growth factor-I, and epidermal growth factor. J Biol Chem 1994, 269(18):13689-13694.
6. Foncea R, Andersson M, Ketterman A, Blakesley V, Sapag-Hagar M, Sugden PH, LeRoith D, Lavandero S: Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J Biol Chem 1997, 272(31):19115-19124.
7. Myers MG Jr, Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J, White MF. Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-I, and interleukin-1 stimulation. J Biol Chem 1994, 269(46):28783-28789.
8. Downward J: Ras signalling and apoptosis. Curr Opin Genet Dev 1998, 8(1):49-54.
9. Dudev H, Datta SR, Franke TF, Birnbaun MJ, Yeo R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275(5300):661-665.
10. Kops GJ, Burgering BM: Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 1999, 77(9):655-665.
11. Myers MG Jr, Backer JM, Sun XJ, Shoeelson S, Hu P, Schlessinger J, Yoakim M, Schaffhausen B, White MF. IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci U S A 1992, 89(21):10350-10354.
12. Rordorf-Nikolic T, Van Horn DJ, Chen D, White MF, Backer JM: Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem 1995, 270(8):3662-3666.
13. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-I. EMBO J 1996, 15(23):6541-6551.
14. Kitamura T, Ogawa W, Sakae H, Hino Y, Kuroda S, Takata M, Matsumoto M, Maeda T, Konishi H, Kikkawa U, Kasuga M: Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. Mol Cell Biol 1998, 18(7):3708-3717.
15. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378(6559):785-789.
16. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-1-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278(5338):687-689.
17. Cardone MH, Roy N, Staniec HR, Salvage GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protein caspase-9 by phosphorylation. Science 1998, 282(5392):1318-1321.
18. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by cellular molecules requires the Aktserine-threonine kinase. Nature 1999, 401(6748):82-85.
19. Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401(6748):86-90.
20. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Fuo P, Hu LS, Anderson JM, Arden KC, Bennis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96(6):857-868.
21. Zheng WH, Kar S, Quirion R: Insulin-like growth factor-I-induced phosphorylation of the forkhead family transcription factor FKHR1 is mediated by Akt in PC12 cells. J Biol Chem 2000, 275(50):39152-39158.
22. Zheng WH, Kar S, Quirion R: FKHR1 and its homologs are novel targets of nerve growth factor Trk receptor signaling. J Neurochem 2002, 80(6):1049-1061.
23. Zheng WH, Kar S, Quirion R: Comparative signaling pathways of insulin-like growth factor-I and brain-derived neurotrophic factor in hippocampal neurons and the role of the insulin-like growth factor pathway in cell survival. J Neurochem 2004, 89(4):844-852.
24. Yin JC, Tully T: CREB and the formation of long-term memory. Curr Opin Neurobiol 1996, 6(2):264-268.
25. Bevilacqua L, Ardenghi P, Schroder N, Bromberg E, Quevedo J, Schnitz PK, Bianchin M, Walz R, Schaeffer E, Medina JH, Izquierdo I: Agents that affect cAMP levels or protein kinase A activity modulate memory consolidation when injected into rat hippocampus but not amygdala. Braz J Med Biol Res 1997, 30(8):967-970.
26. Guzowski JF, McGaugh JL: Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training. Proc Natl Acad Sci U S A 1997, 94(6):2693-2698.
27. Murphy DD, Segal M: Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci U S A 1997, 94(4):1482-1487.
28. Finkbeiner S, Tavaoie SF, Malinak D, Jacobs KM, Greenberg ME: CREB: a major mediator of neuronal neurotrophin responses. Neuron 1997, 19(5):1031-1047.
29. Martin KC, Kandel ER: Cell adhesion molecules, CREB, and the formation of new synaptic connections. Neuron 1996, 17(4):567-570.
30. Pugazhenthi S, Boras T, O’Connor D, Meintzer MK, Heidenreich KA, Reusch JF: Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element binding protein in PC12 cells. Involvement of p38 mitogen-activated protein kinase-mediated signaling. J Biol Chem 1999, 274(5):2829-2837.
31. Meyer TE, Habener JF: Cyclic adenosine 3’,5’-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocr Rev 1993, 14(3):269-290.
32. Ginty DD, Bonni A, Greenberg ME: Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 1994, 77(5):713-725.
33. Sheng M, Thompson MA, Greenberg ME: CREB: a Ca2+-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 1991, 252(5011):1427-1430.
34. Tan Y, Rouse J, Zhang A, Carati S, Cohen P, Comb M: FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 1996, 15(17):4629-4642.
35. Xie H, Rothstein TL: Protein kinase C mediates activation of nuclear cAMP response element-binding protein (CREB) in B lymphocytes stimulated through surface Ig. J Immunol 1995, 154(4):1717-1723.
36. Xing J, Ginty DD, Greenberg ME: Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996, 273(5277):959-963.
37. Du K, Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998, 273(49):32377-32379.
38. Arthur JS, Cohen P: MSK1 is required for CREB phosphorylation in response to mitogens in mouse embryonic stem cells. FEBS Lett 2000, 482(1-2):44-48.
39. Monnier D, Boutillier AL, Giraud P, Chiu R, Aunis D, Feltz P, Zwillev J, Arthur JS, Cohen P: Insulin-like growth factor-I induces phosphorylation of CREB and CREB. J Neurosci 2004, 24(18):4324-4332.
40. Zheng WH, Kar S, Quirion R: Stimulation of protein kinase C modulates insulin-like growth factor-I-induced akt activation in PC12 cells. J Biol Chem 2000, 275(18):13377-13385.
41. Palacios N, Sanchez-Franco F, Fernandez M, Sanchez I, Cacicedo L: Intracellular events mediating insulin-like growth factor I-induced oligodendrocyte development: modulation by cyclic AMP. J Neurochem 2005, 95(4):109-107.
42. Arthur JS, Fong AL, Dwyer JM, Davare M, Reese E, Obrietan K, Impy S: Mitogen- and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins. J Neurosci 2004, 24(18):4324-4332.
43. Smith PF: Neuroprotection against hypoxia-ischemia by insulin-like growth factor-I(IGF-I). Drugs 2003, 6(12):1173-1177.
44. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999, 13(22):2905-2927.
45. Kaplan DR, Miller FD: Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000, 10(3):381-391.
46. Merienne K, Pannetier S, Harel-Bellan A, Sassone-Corsi P: Mitogen-regulated RSK2-CBP interaction controls their kinase and acetylase activities. Mol Cell Biol 2001, 21(20):7089-7096.
47. Bruning JC, Gillette JA, Zhao Y, Bjorbaeck C, Kozak J, Knebel B, Avci H, Hanstein B, Lingohr P, Moller DE, Krone W, Kahn CR, Muller-Wieland D: Ribosomal subunit kinase-2 is required for growth factor-stimulated transcription of the c-fos gene. Proc Nat Acad Sci U S A 1997, 94(9):4772-4777.
48. Beilharz EJ, Russo VC, Butler G, Baker NL, Connor B, Sirimanne ES, Dragunow M, Werther GA, Gluckman PD, Williams CE, Scheepens A: Co-ordinated and cellular specific induction of the components of the IGFI/IGFBP axis in the rat brain following hypoxic-ischemic injury. J Neurochem 2005, 97(2):19-134.
49. Smith PF: Neuroprotection against hypoxia-ischemia by insulin-like growth factor-I(IGF-I). Drugs 2003, 6(12):1173-1177.
50. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999, 13(22):2905-2927.